Astellas and Amgen agreed to pay nearly $125 million to settle a Justice Department investigation into their relationships with charities—and allegations that they used donations as kickbacks to pump up prescriptions. More: Feds say Astellas, Amgen will fork over 5M
read moreBristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. Bristol’s execs? Not so much. More: Bristol arms itself for kidney-cancer fight as Keytruda threatens Opdivo's share Source: fierce
read moreIt’s no surprise that blood thinner Xarelto and eye drug Eylea drove Bayer’s pharma growth again this quarter—they have been for a long time. But cancer drugs Nexavar and Stivarga and hemophilia therapy Jivi unexpectedly held firm despite intense competition.
read moreAbbVie’s Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it’s not likely to be the last. That’s a big switch for the megablockbuster, which has a history of double-digit growth. More: Say
read moreBristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two. An Opdivo-Yervoy combo failed to best Opdivo alone in a phase 2 trial, dashing hopes for a new FDA nod.
read moreThe collaboration will give Sygnature access to software that identifies binding site hot spots on a protein’s surface More: Sygnature and SilcsBio team up Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals